Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PARP7 inhibitor BY101921

An orally available inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration, PARP7 inhibitor BY101921 targets, binds to, and inhibits the activity of PARP7, which restores type I interferon (IFN) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	BY 101921 BY-101921 BY101921

PARP7 inhibitor BY101921

Search NCI's Drug Dictionary